Granted Patent B2

US 12,187,807 · App. 18/452,173 · Granted Jan 7, 2025

Inventors: Karthik Viswanathan (Waltham, MA); Brian Booth (Waltham, MA); Boopathy Ramakrishnan (Waltham, MA); Andrew Wollacott (Waltham, MA); Gregory Babcock (Waltham, MA); Zachary Shriver (Waltham, MA)

Assignee: Visterra, Inc.

C07K16/2896A61K2039/505C07K2317/31C07K2317/76

Abstract

Claims (10)

1. An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), comprising a VH and a VL, wherein the VH comprises:

i. an HCDR1 comprising an amino acid sequence of SEQ ID NO: 602;

ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO: 722; and

iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO: 842; and wherein the VL comprises:

i. an LCDR1 comprising an amino acid sequence of SEQ ID NO: 662,

ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO: 782, and

iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO: 902.

2. The antibody of claim 1 , wherein the VH comprises SEQ ID NO: 482, and the VL comprises SEQ ID NO: 542.

3. A pharmaceutical composition comprising the antibody molecule of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

4. A combination comprising the antibody molecule of claim 1 , and a second therapeutic agent.

Assignments (1)

Continuity (3)

References Cited (141)